Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Background: Metabolic syndrome is present in a subset of individuals harboring a constellation of metabolic risk factors that heightens their likelihood of developing coronary artery disease. Non-alcoholic fatty liver disease (NAFLD) manifests through the incremental accumulation of fat within liver cells in the absence of secondary causes. NAFLD has long been recognized as the hepatic manifestation of metabolic syndrome. Our study seeks to ascertain the prevalence of metabolic syndrome among NAFLD patients at King Khalid University Hospital and to explore the factors associated with metabolic syndrome.

Method And Design: We conducted a retrospective study targeting 1,173 patients diagnosed with NAFLD at King Khalid University Hospital in Riyadh, Saudi Arabia, from March 2020 to March 2021. NAFLD diagnosis was made based on ultrasonographic evidence of a fatty liver, excluding other liver ailments and alcohol intake. Metabolic syndrome was defined according to the National Cholesterol Education Program Adult Treatment Panel III (NCEP/ATP III) criteria, which require at least three of five metabolic risk factors to be present. Statistical analysis was performed using chi-square tests for categorical variables and independent t-tests for continuous variables, with a significance level set at p < 0.05.

Results: Out of 1173 NAFLD participants evaluated, 38.2% met the NCEP/ATPIII criteria for metabolic syndrome. Additionally, 23.8% had at least one metabolic syndrome component coinciding with their ultrasonographically confirmed NAFLD diagnosis. The incidence of NAFLD was not linked to gender. Married individuals constituted a higher percentage (42.8%) of the NAFLD cohort. Elevated blood glucose and triglyceride levels, along with reduced HDL levels, were predominantly observed among the metabolic syndrome components in NAFLD patients.

Conclusion: A significant portion of the NAFLD patient population was concurrently affected by metabolic syndrome. There exists a marked interrelationship between NAFLD and the components of metabolic syndrome. Regular metabolic disorder screenings are recommended for this patient group.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12003115PMC
http://dx.doi.org/10.3389/fendo.2025.1551201DOI Listing

Publication Analysis

Top Keywords

metabolic syndrome
40
metabolic
13
fatty liver
12
nafld
12
syndrome
10
prevalence metabolic
8
non-alcoholic fatty
8
liver disease
8
riyadh saudi
8
saudi arabia
8

Similar Publications

Rare diseases, defined by the 2002 Rare Disease Act, affect fewer than 5 in 10,000 individuals. Rare metabolic bone diseases (MBDs), such as osteogenesis imperfecta, hypophosphatasia, osteopetrosis, and other unclassified disorders, can disrupt bone development and remodeling, posing diagnostic and management challenges. This study analyzed data from the rarembd.

View Article and Find Full Text PDF

Established and Emerging Therapies for Cardiovascular-Kidney-Metabolic Syndrome: Harnessing the Benefits of SGLT-2 Inhibitors, GLP-1 Receptor Agonists, and Beyond.

Heart Lung Circ

September 2025

Lifelong Health Theme, South Australian Health and Medical Research Institute, Adelaide, SA, Australia; Adelaide Medical School, Faculty of Health and Medical Sciences, The University of Adelaide, Adelaide, SA, Australia; Department of Cardiology, Central Adelaide Local Health Network, Adelaide, SA,

Cardiovascular-kidney-metabolic (CKM) syndrome is a term that is increasingly used to describe interconnected conditions that lead to poor health outcomes, including cardiovascular disease, chronic kidney disease, type 2 diabetes, and obesity. Historically, there have been very few targeted pharmacotherapies available that have changed cardiovascular outcomes for people with CKM syndromes; however, over the past decade, new pharmacologic options have rapidly expanded, with strong evidence for cardiovascular and kidney protective benefits in CKM conditions. Of note, sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists have emerged as key therapeutic options and are now widely guideline-endorsed.

View Article and Find Full Text PDF

Is active commuting associated with metabolic syndrome in adults, adolescents, and children? a systematic review and meta-analysis.

Nutr Metab Cardiovasc Dis

July 2025

Instituto de Investigación e Innovación Biomédica de Cádiz, (INiBICA), Cádiz, Spain; GALENO Research Group, Department of Physical Education, Faculty of Education Sciences, University of Cádiz, Puerto Real, Cadiz, Spain; Instituto de Investigación Biosanitaria ibs.GRANADA, Granada, Spain; UGC

Aims: The prevalence of metabolic syndrome (MetS) is increasing annually across all age groups, raising the risk of morbidity, mortality, diabetes and cardiovascular disease in adults, adolescents, and children. Active commuting (AC) provides an opportunity to increase physical activity and reduce the MetS risk. The purpose of this study was to synthesize the available evidence on the prevalence of MetS and MetS risk factors in relation to AC vs non-active commuting among adults, adolescents, and children.

View Article and Find Full Text PDF

The influence of metabolic dysfunction on depressive symptom trajectories: A one-year follow-up study.

J Affect Disord

September 2025

Département de psychiatrie et d'addictologie, Université de Montréal, Montréal, Québec, Canada; Centre de recherche de l'Institut universitaire en santé mentale (CR-IUSMM), Université de Montréal, Montréal, Québec, Canada.

This study explored the role of metabolic syndrome (MetS) and health-related behaviors in the progression of depressive symptoms over a one-year naturalistic follow-up in patients with depressive disorder. Using data from 153 participants recruited through the Signature Biobank at a psychiatric emergency setting, we tested whether MetS mediated the relationship between health-related behaviors such as smoking, alcohol and drug use, and sleep, and depressive symptom trajectories. Linear mixed models revealed that while depressive symptoms significantly decreased over time, higher MetS score was associated with a slower improvement in depressive symptoms.

View Article and Find Full Text PDF

Diet and obesity contribute to insulin resistance and type 2 diabetes, in part via the gut microbiome. To explore the role of gut-derived metabolites in this process, we assessed portal/peripheral blood metabolites in mice with different risks of obesity/diabetes, challenged with a high-fat diet (HFD) + antibiotics. In diabetes/obesity-prone C57BL/6J mice, 111 metabolites were portally enriched and 74 were peripherally enriched, many of which differed in metabolic-syndrome-resistant 129S1/129S6 mice.

View Article and Find Full Text PDF